AAL

Crispr Therapeutics Stock Pops on Vertex Stake

CRSP hit a multi-month low on Friday

Dec 24, 2018 at 11:43 AM
facebook X logo linkedin


Crispr Therapeutics AG (NASDAQ:CRSP) is trading up 9.9% at $24.98 today, after it was revealed Friday evening that cystic fibrosis specialist Vertex Pharmaceuticals (VRTX) took a 10.1% stake in the gene editing company. On Friday, CRSP stock touched a nearly 52-week low of $22.22, as it's struggled mightily in the second half of the year.

To be more specific, the shares traded as high as $73.88 in late May, but since then have been stuck in a relentless downtrend. In just the past three months, Crispr Therapeutics has shed 45%, and not surprisingly ended up in oversold territory, like many stocks across the market, according to its 14-day Relative Strength Index (RSI) of 22. 

Still, analysts have mostly remained bullish. Of the 11 brokerage firms in coverage, seven say to buy CRSP. Even more notable, the average 12-month price target from the brokerage bunch stands all the way up at $66.17.

As for options traders, near-term open interest remains heavily call-skewed, according to the Schaeffer's put/call open interest ratio (SOIR) of 0.56, which ranks in the 9th annual percentile. On the other hand, put buying has picked up at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), with the 10-day put/call volume ratio of 0.81 arriving in the 80th annual percentile. Said differently, there's been a greater-than-usual interest in put buying relative to call buying in recent weeks.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.